Research programme: muscarinic receptor agonists and antagonists - ACADIA/Sepracor

Drug Profile

Research programme: muscarinic receptor agonists and antagonists - ACADIA/Sepracor

Alternative Names: 108LM39-36; AC 90987; AC-260584

Latest Information Update: 26 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ACADIA Pharmaceuticals; Sepracor
  • Class
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued CNS disorders; Cognition disorders; Neuropathic pain; Psychotic disorders; Schizophrenia

Most Recent Events

  • 21 Jan 2005 ACADIA and Sepracor entered into an agreement to jointly develop therapeutic agents for the treatment of CNS disorders
  • 04 Aug 2004 Preclinical trials in Schizophrenia in USA (unspecified route)
  • 07 Apr 2003 Data presented at the 225th American Chemical Society Meeting (225th-ACS) have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top